HALO
Halozyme Therapeutics Inc
109.90$
+2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +255.6% | -70.7% | – | – | +671.8% | +287.0% | +130.7% | +56.0% | -0.3% | +311.7% | -24.5% | +29.5% | +37.5% | +79.3% | +8.6% | +115.8% | -52.0% | +29.1% | +36.5% | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | |
| – | +213.3% | -45.6% | – | – | +740.9% | -45.0% | +38.2% | -6.1% | +215.9% | -73.8% | +324.5% | +470.7% | +264.0% | +28.7% | +13.5% | -6.2% | -67.5% | +349.3% | -4.8% | +87.7% | +71.1% | +38.1% | -17.1% | +91.6% | |
| – | +331.5% | -103.4% | – | – | +624.0% | +553.3% | +136.9% | +58.4% | -5.4% | +341.7% | -26.1% | +17.8% | +8.3% | +101.2% | +7.3% | +151.5% | -50.4% | +6.2% | +49.0% | +61.4% | +43.9% | +22.3% | +34.4% | +27.5% | |
| – | – | – | – | +56.8% | -9.8% | +123.1% | +115.2% | +28.0% | -8.6% | +11.2% | +21.7% | +38.0% | -17.5% | +17.0% | +61.8% | -0.1% | -0.3% | -6.3% | -75.7% | +4.2% | +86.7% | +14.6% | +3.5% | +3.1% | |
| – | – | – | +3,204.4% | +32.9% | +102.3% | +61.4% | +31.2% | +3.9% | -0.5% | +19.7% | +37.1% | +30.4% | +11.1% | +11.4% | +14.6% | +17.4% | +13.0% | +27.1% | -40.8% | +10.0% | +185.2% | +3.9% | +3.5% | +34.2% | |
| – | +59.6% | +0.4% | +11,582.1% | +50.1% | +18.3% | +96.6% | +85.6% | +22.0% | -6.9% | +13.1% | +25.4% | +36.0% | -10.3% | +15.2% | +47.6% | +3.9% | +3.2% | +3.3% | -63.3% | +7.5% | +194.5% | +18.2% | +1.7% | -9.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -185.6% | – | – | +91.3% | -3.0% | +26.2% | +63.4% | +48.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | +70.5% | -6.8% | +284.1% | +10.0% | -17.9% | -35.6% | +75.3% | -63.1% | +125.2% | +10.7% | -3.6% | +0.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -229.5% | – | – | +92.2% | +0.2% | +39.9% | +59.9% | -16.2% | |
| – | – | +9,786.4% | -95.5% | -8,210.1% | – | – | – | – | – | – | – | – | +86.5% | -7.7% | -67.0% | -217.1% | – | -102.0% | – | -71,156.2% | – | +42.6% | +69.4% | +32.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -227.6% | – | – | +212.0% | -49.8% | +39.3% | +57.7% | -28.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -180.5% | – | – | +89.0% | +13.1% | +43.2% | +45.3% | -12.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.